IESC IESC

September 21, 2016 - 1:08pm EST by

member

						2016	2017
Price:		15.42		EPS		1.32	1.69
Shares Out. (in M):		21		P/E		11.7	9.1
Market Cap (in $M):		331		P/FCF		10	8
Net Debt (in $M):		7		EBIT		29	37
TEV (in $M):		338		TEV/EBIT		11.6	9

Description

Sign up or Log In

Sign up for free guest access to view investment ideas with a 45-day delay and read the full report.

Log in to read the full report.

2 show sort by

You are not eligible to view 1 messages. To gain access to more recent message posts signup free for membership.

9	member 12/27/19 9:10AM MLNT files for Ch.11 in a prepack with no equity recovery
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility ~ Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations ~ MORRISTOWN, N.J., December 27, 2019... login to read the rest 1 view available tags
8	member 11/13/19 2:01PM Re: Victory Lap 6
congrats on a great call (and an even better IRR)! thanks for sharing. 1 view available tags
6	member 11/13/19 1:27PM Victory Lap
Not much meat left on this bone, we are closing the recommendation with the stock down nearly 80%. Although it is probably an actual 0 in the next 3-6 months, borrow is expensive and we're... login to read the rest 2 view available tags
5	member 11/12/19 5:25PM 10-Q discloses likely bankruptcy with no equity recovery
There are certain financial-related covenants under our Deerfield Facility, as amended in January 2019, including requirements that we (i) file an Annual Report on Form 10-K for the year ending December 31, 2019, with an... login to read the rest 1 view available tags
4	member 11/07/19 8:18AM Vatera
MLNT 8-k today confirming the company will not meet requireements necessary to get remaining commitment from Vatera. We still expect outright default in next few months or highly dilutive equity dump. Given the likelihood that a... login to read the rest 2 view available tags
3	member 10/24/19 4:34PM Re: Re: CABP approval 2
Congrats on the phenomenal timing on this short! Sure does look like the only alternatives here are some sort of highly dilutive financing or a DIP loan. 2 view available tags
2	member 10/24/19 4:24PM Re: CABP approval 1
Also, they mentioned they are holding off on rolling-out the drug until they figure out their liquidity situation. So another reminder for the market that they are up sht creek. That's hitting the stock hard 2 view available tags
1	member 10/24/19 4:07PM CABP approval
FDA just approved BAXDELA for treatement of CABP (as expected). We see any pop from this as a sell the news opportunity. view available tags

load more messages